GB2568471B - Use of cannabinoids in the treatment of epilepsy - Google Patents

Use of cannabinoids in the treatment of epilepsy Download PDF

Info

Publication number
GB2568471B
GB2568471B GB1718862.4A GB201718862A GB2568471B GB 2568471 B GB2568471 B GB 2568471B GB 201718862 A GB201718862 A GB 201718862A GB 2568471 B GB2568471 B GB 2568471B
Authority
GB
United Kingdom
Prior art keywords
cannabinoids
epilepsy
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB1718862.4A
Other languages
English (en)
Other versions
GB2568471A (en
GB201718862D0 (en
Inventor
Guy Geoffrey
Knappertz Volker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GW Research Ltd
Original Assignee
GW Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60788456&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB2568471(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by GW Research Ltd filed Critical GW Research Ltd
Priority to GB1718862.4A priority Critical patent/GB2568471B/en
Publication of GB201718862D0 publication Critical patent/GB201718862D0/en
Priority to CN201880080175.4A priority patent/CN111629756A/zh
Priority to EP18808075.8A priority patent/EP3710058B1/en
Priority to MX2020005147A priority patent/MX2020005147A/es
Priority to AU2018366443A priority patent/AU2018366443A1/en
Priority to CA3082433A priority patent/CA3082433A1/en
Priority to NZ764569A priority patent/NZ764569B2/en
Priority to EP24200897.7A priority patent/EP4487860A3/en
Priority to FIEP18808075.8T priority patent/FI3710058T3/fi
Priority to ES18808075T priority patent/ES2991947T3/es
Priority to DK18808075.8T priority patent/DK3710058T3/da
Priority to KR1020207015573A priority patent/KR102786614B1/ko
Priority to JP2020526576A priority patent/JP7391019B2/ja
Priority to US16/764,701 priority patent/US20210169824A1/en
Priority to PCT/GB2018/053315 priority patent/WO2019097238A1/en
Priority to RU2020119390A priority patent/RU2020119390A/ru
Priority to BR112020009508-7A priority patent/BR112020009508A2/pt
Publication of GB2568471A publication Critical patent/GB2568471A/en
Priority to IL274633A priority patent/IL274633A/en
Priority to MX2023012352A priority patent/MX2023012352A/es
Publication of GB2568471B publication Critical patent/GB2568471B/en
Application granted granted Critical
Priority to JP2023170155A priority patent/JP7723711B2/ja
Priority to AU2024216397A priority patent/AU2024216397A1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
GB1718862.4A 2017-11-15 2017-11-15 Use of cannabinoids in the treatment of epilepsy Expired - Fee Related GB2568471B (en)

Priority Applications (21)

Application Number Priority Date Filing Date Title
GB1718862.4A GB2568471B (en) 2017-11-15 2017-11-15 Use of cannabinoids in the treatment of epilepsy
BR112020009508-7A BR112020009508A2 (pt) 2017-11-15 2018-11-15 canabidiol para uso no tratamento de convulsões associadas à síndrome de lennox-gastaut, e, método para tratar convulsões associadas à síndrome de lennox-gastaut.
KR1020207015573A KR102786614B1 (ko) 2017-11-15 2018-11-15 레녹스-가스토 증후군 관련 발작의 치료에서 칸나비노이드의 용도
PCT/GB2018/053315 WO2019097238A1 (en) 2017-11-15 2018-11-15 Use of cannabinoids in the treatment of seizures associated with lennox-gastaut syndrome
MX2020005147A MX2020005147A (es) 2017-11-15 2018-11-15 Uso de cannabinoides en el tratamiento de convulsiones asociadas al sindrome de lennox-gastaut.
AU2018366443A AU2018366443A1 (en) 2017-11-15 2018-11-15 Use of cannabinoids in the treatment of seizures associated with Lennox-Gastaut syndrome
CA3082433A CA3082433A1 (en) 2017-11-15 2018-11-15 Use of cannabinoids in the treatment of seizures associated with lennox-gastaut syndrome
NZ764569A NZ764569B2 (en) 2018-11-15 Use of cannabinoids in the treatment of seizures associated with lennox-gastaut syndrome
EP24200897.7A EP4487860A3 (en) 2017-11-15 2018-11-15 Use of cannabinoids in the treatment of epilepsy
FIEP18808075.8T FI3710058T3 (fi) 2017-11-15 2018-11-15 Kannabidiolin käyttö lamotrigiinin lisäksi kohtausten hoitoon, jotka liittyvät Lennox-Gastaut-oireyhtymään
ES18808075T ES2991947T3 (es) 2017-11-15 2018-11-15 Uso de cannabidiol además de lamotrigina para el tratamiento de las convulsiones asociadas al síndrome de Lennox-Gastaut
DK18808075.8T DK3710058T3 (da) 2017-11-15 2018-11-15 Anvendelse af cannabidiol ud over lamotrigin til behandling af anfald forbundet med lennox-gastauts syndrom
CN201880080175.4A CN111629756A (zh) 2017-11-15 2018-11-15 大麻素在治疗与Lennox-Gastaut综合征相关的癫痫发作中的用途
JP2020526576A JP7391019B2 (ja) 2017-11-15 2018-11-15 レノックス・ガストー症候群に関連した発作の治療におけるカンナビノイドの使用
US16/764,701 US20210169824A1 (en) 2017-11-15 2018-11-15 Use of cannabinoids in the treatment of seizures as associated with lennox-gastaut syndrome
EP18808075.8A EP3710058B1 (en) 2017-11-15 2018-11-15 Use of cannabidiol in addition to lamotrigine for the treatment of seizures associated with lennox-gastaut syndrome
RU2020119390A RU2020119390A (ru) 2017-11-15 2018-11-15 Применение каннабиноидов при лечении приступов, связанных с синдромом леннокса-гасто
IL274633A IL274633A (en) 2017-11-15 2020-05-13 Use of cannabinoids in the treatment of seizures associated with Lennox-Gastaut syndrome
MX2023012352A MX2023012352A (es) 2017-11-15 2020-07-13 Uso de cannabinoides en el tratamiento de convulsiones asociadas al sindrome de lennox-gastaut.
JP2023170155A JP7723711B2 (ja) 2017-11-15 2023-09-29 レノックス・ガストー症候群に関連した発作の治療におけるカンナビノイドの使用
AU2024216397A AU2024216397A1 (en) 2017-11-15 2024-08-28 Use of cannabinoids in the treatment of seizures associated with Lennox-Gastaut syndrome

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1718862.4A GB2568471B (en) 2017-11-15 2017-11-15 Use of cannabinoids in the treatment of epilepsy

Publications (3)

Publication Number Publication Date
GB201718862D0 GB201718862D0 (en) 2017-12-27
GB2568471A GB2568471A (en) 2019-05-22
GB2568471B true GB2568471B (en) 2022-04-13

Family

ID=60788456

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1718862.4A Expired - Fee Related GB2568471B (en) 2017-11-15 2017-11-15 Use of cannabinoids in the treatment of epilepsy

Country Status (16)

Country Link
US (1) US20210169824A1 (enExample)
EP (2) EP4487860A3 (enExample)
JP (2) JP7391019B2 (enExample)
KR (1) KR102786614B1 (enExample)
CN (1) CN111629756A (enExample)
AU (2) AU2018366443A1 (enExample)
BR (1) BR112020009508A2 (enExample)
CA (1) CA3082433A1 (enExample)
DK (1) DK3710058T3 (enExample)
ES (1) ES2991947T3 (enExample)
FI (1) FI3710058T3 (enExample)
GB (1) GB2568471B (enExample)
IL (1) IL274633A (enExample)
MX (2) MX2020005147A (enExample)
RU (1) RU2020119390A (enExample)
WO (1) WO2019097238A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB2514054A (en) 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2541191A (en) 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
GB2560019A (en) 2017-02-27 2018-08-29 Gw Res Ltd Use of cannabinoids in the treatment of leukaemia
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
GB201910389D0 (en) 2019-07-19 2019-09-04 Gw Pharma Ltd Novel compounds, methods for their manufacture, and uses thereof
GB2588576A (en) 2019-08-27 2021-05-05 Gw Res Ltd Use of cannabinoids in the treatment of dyskinesia associated with Parkinson's disease
GB201916846D0 (en) 2019-11-19 2020-01-01 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB201916849D0 (en) 2019-11-19 2020-01-01 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB201916977D0 (en) 2019-11-21 2020-01-08 Gw Res Ltd Cannibidol-type cannabinoid compound
GB201916974D0 (en) 2019-11-21 2020-01-08 Gw Res Ltd Cannabidol-type cannabinoid compound
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
GB202009321D0 (en) 2020-06-18 2020-08-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
KR102891881B1 (ko) 2020-07-16 2025-11-26 주식회사 엘지에너지솔루션 듀얼 슬롯 다이 코터
GB2597304A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with shaken baby syndrome
WO2022017936A1 (en) * 2020-07-20 2022-01-27 GW Research Limited Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB2597280A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with auriculotemporal syndrome
GB202013765D0 (en) 2020-09-02 2020-10-14 Gw Res Ltd Method of preparing cannabinoids
EP4412619A4 (en) * 2021-10-04 2025-11-12 Marinus Pharmaceuticals Inc GANAXOLONE FOR THE TREATMENT OF BOURNEVILLE'S TUBEROUS SCLEROSIS AND EPILEPTIC DISORDERS
US12036228B2 (en) 2022-04-12 2024-07-16 Shackelford Pharma Inc. Treatment of seizure disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2531282A (en) * 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2539472A (en) * 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106999598B (zh) 2014-05-29 2022-02-08 鲜切发展有限责任公司 稳定的大麻素类化合物制剂
US20170224634A1 (en) * 2014-05-29 2017-08-10 Insys Development Company, Inc. Stable cannabinoid formulations
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2531282A (en) * 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2539472A (en) * 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Epilepsia, vol. 58, No. 9, 2017, Gaston et al. "Interactions between cannabidiol and commonly used antiepileptic drugs", pages 1586-1592 *
Epilepsy & Behavior, vol. 29, 2013, pages 574-577 *
http://web.archive.org/web/20100902130020/http:/www.cannabis-med.org/studies/ww_en_db_study_show.php?s_id=173&&search_pattern=EPILEPSY [online] 2005, Clinical Studies and Case Reports *
https://www.aesnet.org/meetings_events/annual_meeting_abstracts/view/1868751 [online] 2014, American Epilepsy Society, Annual Meeting Abstracts: View *
https://www.neurologyadvisor.com/aan-2017-coverage/aan-2017-cannabidiol-reduces-drop-seizures-in-lennox-gastaut-syndrome/article/652931/ [online] 26 April 2017, Neurology Advisor *
The Lancet Neurology, vol. 15, 2016, pages 270-278 *

Also Published As

Publication number Publication date
RU2020119390A (ru) 2021-12-15
JP2021502992A (ja) 2021-02-04
KR20200088356A (ko) 2020-07-22
CA3082433A1 (en) 2020-05-15
EP4487860A3 (en) 2025-04-02
WO2019097238A1 (en) 2019-05-23
AU2018366443A1 (en) 2020-06-11
RU2020119390A3 (enExample) 2021-12-15
US20210169824A1 (en) 2021-06-10
CN111629756A (zh) 2020-09-04
EP3710058B1 (en) 2024-10-09
ES2991947T3 (es) 2024-12-05
MX2023012352A (es) 2023-10-31
AU2024216397A1 (en) 2024-09-19
KR102786614B1 (ko) 2025-03-26
GB2568471A (en) 2019-05-22
JP7723711B2 (ja) 2025-08-14
BR112020009508A2 (pt) 2020-10-13
JP2023168448A (ja) 2023-11-24
DK3710058T3 (da) 2024-11-04
EP4487860A2 (en) 2025-01-08
FI3710058T3 (fi) 2024-11-11
EP3710058A1 (en) 2020-09-23
NZ764569A (en) 2024-11-29
MX2020005147A (es) 2020-08-20
JP7391019B2 (ja) 2023-12-04
IL274633A (en) 2020-06-30
GB201718862D0 (en) 2017-12-27

Similar Documents

Publication Publication Date Title
IL274769A (en) Use of cannabinoids in the treatment of epilepsy
GB2568809B (en) Use of cannabinoids in the treatment of epilepsy
IL276217A (en) Use of cannabinoids in the treatment of epilepsy
GB2568471B (en) Use of cannabinoids in the treatment of epilepsy
GB201819573D0 (en) Use of cannabinoids in the treatment of epilepsy
IL281793A (en) Use of cannabinoids in the treatment of epilepsy
PT3334422T (pt) Utilização de ácido canabidiólico no tratamento de epilepsia
GB201902427D0 (en) Use of cannabinoids in the treatment of epilepsy
GB201510664D0 (en) Use of cannabinoids in the treatment of epilepsy
GB201703115D0 (en) Use of cannabinoids in the treatment of leukaemia
GB201614522D0 (en) Use of cannabinoids in the treatment of multiple myeloma
GB201411496D0 (en) Use of 7-Oh-Cannabidiol (7-Oh-CBD) and/or 7-Oh-Cannabidvarin (7-Oh-CBDV) in the treatment of epilepsy
GB201900797D0 (en) Use of cannabinoids in the treatment of comorbidities associated with epilepsy
PL3157511T3 (pl) Zastosowanie kannabinoidów w leczeniu padaczki
GB201418170D0 (en) Use of cannabidiol in the treatment of intractable epilepsy
GB201418166D0 (en) Use of cannabidiol in the treatment of intractable epilepsy
GB201418169D0 (en) Use of cannabidiol in the treatment of intractable epilepsy
ZA201607415B (en) Antibody-drug-conjugate and its use for the treatment of cancer
GB201515986D0 (en) Use of cannabinoids in the treatment of mental disorders
GB201418172D0 (en) Use of cannabidiol in the treatment of intractable epilepsy
IL254142B (en) Tredifitant for use in the treatment of a disease or medical condition that responds to Tredifitent
PL3277280T3 (pl) Izomiosmina do zastosowania w leczeniu chorób autoimmunologicznych
GB2549278B (en) Use of cannabidivarin in the treatment of autism spectrum disorder
GB2564459B (en) Use of cannabinoids in the treatment of a neurodegenerative disease or disorder
IL275349A (en) Use of hM4Di in the treatment of seizure disorders

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20241115